Bortezomib, Thalidomide, and Dexamethasone With or Without Daratumumab for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Bortezomib, Thalidomide, and Dexamethasone With or Without Daratumumab for Transplantation-Eligible Patients With Newly Diagnosed Multiple Myeloma (CASSIOPEIA): Health-Related Quality of Life Outcomes of a Randomised, Open-Label, Phase 3 Trial
Lancet Haematol 2020 Dec 01;7(12)e874-e883, M Roussel, P Moreau, B Hebraud, K Laribi, A Jaccard, M Dib, B Slama, V Dorvaux, B Royer, L Frenzel, S Zweegman, SK Klein, A Broijl, KS Jie, J Wang, V Vanquickelberghe, C de Boer, T Kampfenkel, KS Gries, J Fastenau, P SonneveldFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.